Frontiers in endocrinologyOct 20, 2026

Safety, timing, lasting effects, and body changes of weight-loss drugs during cosmetic surgery

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Oct 21, 2026

Abstract

GLP-1 receptor agonists may produce double-digit percentage weight loss, influencing the demand for aesthetic surgery.

Weight loss from GLP-1 receptor agonists can lead to new challenges in body contouring and facial rejuvenation due to skin redundancy and tissue laxity.
Delayed gastric emptying associated with incretin therapy may increase the risk of pulmonary aspiration in symptomatic patients.
Gastrointestinal side effects tend to peak during the escalation of GLP-1 RA doses, potentially complicating patient management.
Rapid weight loss with these agents is linked to loss of lean mass and nutritional inadequacies during periods of reduced appetite.
Frequent weight regain after discontinuation of GLP-1 RAs could threaten the long-term effectiveness of aesthetic surgeries.
A proposed framework for timing elective procedures involves assessing weight stability and symptom burden in patients using GLP-1 RAs.

Simplified

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual incretin agonists have transformed the management of obesity and type 2 diabetes and are rapidly reshaping the population seeking aesthetic surgery. By producing double-digit percentage weight loss, these agents expand eligibility for elective procedures while generating new patterns of skin redundancy, soft-tissue laxity, and facial volume depletion that drive demand for body contouring and facial rejuvenation. At the same time, incretin therapy introduces distinct perioperative considerations: delayed gastric emptying with possible pulmonary aspiration in symptomatic patients, gastrointestinal adverse effects that peak during dose escalation, loss of lean mass with rapid weight reduction, nutritional inadequacy during profound appetite suppression, and frequent weight regain after drug discontinuation, which threatens the durability of surgical results. This mini-review synthesizes current evidence on the mechanisms of GLP-1 RAs relevant to the reconstructive surgical patient, summarizes the evolving guidance from anesthesia societies, moving from blanket preoperative withholding to individualized risk stratification, reviews emerging outcome data on body contouring in GLP-1 RA users, and discusses body composition, sarcopenia risk, and nutritional optimization. We propose a pragmatic framework, anchored in weight stability and symptom burden, for timing elective aesthetic procedures relative to GLP-1 RA initiation, escalation, and maintenance, along with a multidisciplinary perioperative algorithm that links the endocrinologist, plastic surgeon, and anesthesiologist. As incretin-based pharmacotherapy expands globally, coordinated endocrine-surgical-anesthetic care will be essential to maximize safety, functional recovery, and patient satisfaction in the GLP-1 era.

Full Text

Full text is available at the source.

View Full Text ↗

Safety, timing, lasting effects, and body changes of weight-loss drugs during cosmetic surgery

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief